<DOC>
	<DOCNO>NCT02285465</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics ascend multiple oral dos ASP3700 healthy subject .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics ASP3700 Healthy Subjects</brief_title>
	<detailed_description>Subjects confine clinic 18 day .</detailed_description>
	<criteria>Subject skin type I , II III ( Fitzpatrick classification ) . Subject body mass index ( BMI ) 18.5 30.0 kg/m2 , inclusive . The subject weigh least 50 kg screening . Female subject pregnant within 6 month prior screen assessment breast feeding within 3 month prior screen . Subject know suspected hypersensitivity ASP3700 component formulation use . Subject respond capsaicin challenge screen day 1 . A nonresponder define dermal blood flow ( DBF ) ≤ 100 % increase baseline ( normal skin ) compare DBF 30 minute application 0.4 mL ( approximately 300 µg ) capsaicin cream ( Axsain® , 0.075 % capsaicin w/w ) . Subject respond histamine challenge screen day 1 . A nonresponder define insufficient wheal ( mean diameter &lt; 0.5 cm ) and/or flare ( mean diameter &lt; 2 cm ) reaction ( visually assess measure trained staff member ) 10 minute histamine intradermal injection . Subject history suicide attempt suicidal behavior . Any suicidal ideation within last 3 month ( level 4 5 1 item scale ) , significant risk commit suicide , judge investigator use CSSRS screen admission clinical unit day 1 . Subject liver function test ( aspartate aminotransferase [ AST ] , Alanine aminotransferase [ ALT ] , alkaline phosphatase [ ALP ] , gamma glutamyl transferase , total bilirubin [ TBL ] ) upper limit normal ( ULN ) . In case assessment may repeat day 1 . Subject clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy time dose ) . Subject history clinically significant reaction cannabis synthetic cannabinoids judge investigator . Subject history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy , judge investigator . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior admission clinical unit . Subject clinically significant abnormality follow investigator 's review physical examination , electrocardiogram ( ECG ) protocol define clinical laboratory test screen day 1 . Subject mean pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure ( SBP ) &gt; 140 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( vital sign measurement take triplicate subject rest supine position 5 minute ; pulse measure automatically ) day 1 . If mean pulse , mean SBP mean DBP range specify , 1 additional triplicate measurement may take . Subject mean QTc ( F ) interval &gt; 430 m ( male ) &gt; 450 m ( female ) day 1 . If mean QTc ( F ) exceed limit , 1 additional triplicate ECG take . Subject use prescribe nonprescribed drug ( include antihistamine , vitamin , natural herbal remedy , e.g. , St. John 's wort ) 2 week prior study drug administration , except occasional use paracetamol ( 2 g/day ) . Subject use nicotinecontaining product within 6 month prior admission clinical unit day 1 . Subject history drinking &gt; 21 unit alcohol per week male subject &gt; 14 unit alcohol female subject ( 1 unit = 10 g pure alcohol = 250 mL beer [ 5 % ] 35 mL spirit [ 35 % ] 100 mL wine [ 12 % ] ) within 3 month prior admission clinical unit day 1 . Subject use drug abuse within 3 month prior admission clinical unit day 1 . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior admission clinical unit day 1 . Subject consume grapefruit , grapefruitcontaining product , Seville orangecontaining product , caffeine , xanthine , quinidine theobromine containing product within 72 hour prior admission clinical unit day 1 . Subject significant blood loss , donate 1 unit ( 500 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit day 1 . Subject positive serology test hepatitis B surface antigen ( HBsAg ) , hepatitis A virus antibody ( immunoglobulin M ) ( antiHAV [ IgM ] ) , hepatitis C virus antibody ( antiHCV ) , antibodies human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Subject participate clinical study treat investigational drug within 3 month 5 halflives , whichever longer , prior screen . Subject skin disease , acute chronic ( e.g. , atopic dermatitis ) active dermatological condition , local pigmentary disorder , body art ( e.g. , tattoo ) might interfere clinical study assessment . Subject condition , investigator 's opinion , make subject unsuitable clinical study participation . Subject employee Astellas Group Contract Research Organization ( CRO ) involve clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>ASP3700</keyword>
</DOC>